CAMBRIDGE, Mass., May 22 /PRNewswire-FirstCall/ -- Javelin Pharmaceuticals, Inc. , today announced that Michael T. Sheckler, MBA, Vice President of Business Development, will deliver a plenary presentation on “Prognosticating Pain Management: From Pipeline to Practitioner” at the 2nd Annual Specialty Pharma Global Summit. The meeting is an elite forum at which Big Pharma, Biotech, and Drug Delivery companies network with the fastest growing specialty pharma companies and exchange information on growth opportunities for pipeline and business development. Mr. Sheckler will also participate in a panel, “Partnering in Specialty Pharma.”
The 2nd Annual Specialty Pharma Global Summit will take place at the Hyatt Regency in New Brunswick, NJ on Tuesday, May 23 to Wednesday, May 24, 2006. Mr. Sheckler will participate in the panel on Tuesday, May 23, at 4:45 PM and deliver his plenary lecture on Wednesday May 24, at 11:30 AM. He will be available for one-on-one meetings during the conference.
For more information about the 2nd Annual Specialty Pharma Global Summit, visit http://www.srinstitute.com/conf_page.cfm?instance_id=27&web_id=807&pid=415
About Javelin
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit the company’s website at http://www.javelinpharmaceuticals.com.
Forward Looking Statement
This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.
Javelin Pharmaceuticals, Inc.
CONTACT: June Gregg of Javelin Pharmaceuticals, Inc., +1-212-554-4550,jgregg@javelinpharmaceuticals.com; or Bryan Murphy of LaVoie Group, +1-781-596-0200 ext. 105, bmurphy@lavoiegroup.com, for Javelin Pharmaceuticals,Inc.
Web site: http://www.javelinpharmaceuticals.com/
